Montelukast is not effective in controlling allergic symptoms outside the airways: a randomised double-blind placebo-controlled crossover study

International Archives of Allergy and Immunology
Lauri LehtimäkiTari Haahtela

Abstract

Subjects with atopic syndrome often perceive symptoms from various organs. A single drug that acts on all the syndrome's manifestations would be the ideal treatment. The role of montelukast, a cysteinyl-leukotriene receptor antagonist, is established in treating allergic rhinitis and asthma, but its ability to alleviate atopic symptoms outside the airways is controversial. Our aim was to assess if montelukast could be used to treat all the various symptoms seen in subjects with atopic syndrome. A randomised, double-blind, placebo-controlled crossover study on the effect of montelukast in atopic syndrome was conducted during the 2007 pollen season. Forty-five pollen-sensitised subjects who had allergic symptoms from both the upper and lower airways and allergic symptoms outside the airways (conjunctivitis, oral symptoms, eczema and/or urticaria) were recruited. The primary outcome parameter was the allergic symptoms, which were assessed using a questionnaire. Secondary outcome parameters were lower-airway inflammation (exhaled nitric oxide) and the need for rescue medication (inhaled beta2-agonists and oral antihistamines). There were no differences between montelukast and placebo treatments in allergic symptoms, in exhaled NO c...Continue Reading

Associated Clinical Trials

Citations

Oct 22, 2018·The Cochrane Database of Systematic Reviews·Leila FergusonRintaro Mori
Nov 16, 2018·Expert Opinion on Pharmacotherapy·Ludger KlimekPeter Valentin Tomazic
May 20, 2018·International Journal of Clinical Pharmacy·Weng Khong Chin, Shaun Wen Huey Lee
Nov 9, 2017·Journal of Clinical Pharmacy and Therapeutics·W K Chin
Dec 23, 2009·Current Opinion in Allergy and Clinical Immunology

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Related Papers

The Annals of Pharmacotherapy
Jamie L TrautShailendra Saxena
Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre
Ceyda AnarNur Yucel
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
William W BusseJonathan M Edelman
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
Allan LuskinDonald D Yin
© 2021 Meta ULC. All rights reserved